The Impact of Antibiotic Prophylaxis on Incidence of Post-bronchoscopy Fever and Change of Serum Cytokines

This study has been completed.
Sponsor:
Information provided by:
Seoul National University Hospital
ClinicalTrials.gov Identifier:
NCT01089218
First received: March 14, 2010
Last updated: July 19, 2011
Last verified: July 2011
  Purpose

Fever can develop after fiberoptic bronchoscopy (FB) in about 2.5 - 16 % of adult patients. We evaluated the impact of oral amoxicillin/clavulanate (AC) on incidence of postbronchoscopic fever and pneumonia.


Condition Intervention Phase
Fever
Pneumonia
Drug: oral amoxicillin/clavulanate 1g (875/125mg)
Drug: control
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Prevention
Official Title: The Impact of Antibiotic Prophylaxis on Incidence of Post-bronchoscopy Fever and Change of Serum Cytokines

Resource links provided by NLM:


Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • The incidence of fever [ Time Frame: 24 hr after bronchoscopy ] [ Designated as safety issue: Yes ]
    time frame for body temperature 24hr before and after bronchoscopy every 4hrs


Secondary Outcome Measures:
  • change of serum cytokines level [ Time Frame: before bronchoscopy and 24hr after bronchoscopy ] [ Designated as safety issue: Yes ]
    Time frame for cytokine measurement 24hr before brochoscopy - 1hr after bronchosocpy - 24hr after brochoscopy


Enrollment: 241
Study Start Date: April 2008
Study Completion Date: February 2010
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: control
control without intervention
Drug: control
no intervention with the same procedure of FB
Other Name: control
Active Comparator: Amoxicillin/clavulanate Drug: oral amoxicillin/clavulanate 1g (875/125mg)
oral amoxicillin/clavulanate 1g (875/125mg) on the day of the procedure 30 minutes prior to the FB
Other Name: prophylaxis group

Detailed Description:

For the population being undergone with bronchoscopy, the clinical signs and procedural measures for complication of bronchoscopy and cytokines will be checked.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adult patients (aged 18 years or older) who underwent FB

Exclusion Criteria:

  • concurrent treatment with antibiotics or systemic corticosteroid
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01089218

Sponsors and Collaborators
Seoul National University Hospital
Investigators
Study Director: Deog Kyeom Kim, MD. Seoul Metropolitan Government, Seoul National University Boramae Medical Center, 39 Boramae-Gil, Dongjak-Gu, Seoul, Republic of Korea 156-707.
  More Information

No publications provided by Seoul National University Hospital

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Deog Kyeom Kim, MD, Seoul Metropolitan Government, Seoul National University Boramae Medical Center
ClinicalTrials.gov Identifier: NCT01089218     History of Changes
Other Study ID Numbers: postFB fever
Study First Received: March 14, 2010
Last Updated: July 19, 2011
Health Authority: Korea: Institutional Review Board

Keywords provided by Seoul National University Hospital:
bronchoscopy
post-bronchoscopy fever
pneumonia
cytokines
amoxicillin/clavulanate
prophylaxis

Additional relevant MeSH terms:
Fever
Pneumonia
Body Temperature Changes
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Signs and Symptoms
Amoxicillin
Amoxicillin-Potassium Clavulanate Combination
Clavulanic Acid
Clavulanic Acids
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 29, 2014